Compugen (CGEN) reports an in-line Q2 loss as revenue doubles but falls slightly below analyst estimates.
Stock Earnings Results
August 3, 2026
Table of Contents
August 3, 2026
Compugen Ltd. (NASDAQ: CGEN) reported second-quarter 2026 results with a loss per share in line with expectations, higher revenue, continued pipeline progress, and a cash runway expected to fund operations into 2029.
Compugen is a clinical-stage cancer immunotherapy company using AI and machine learning through its Unigen platform to discover new drug targets and develop immuno-oncology therapies.
The company reported a loss of $0.07 per share, in line with estimates. Revenue came in at $2.60 million, below estimates of $2.70 million, though revenue growth was 107.0%.
Compugen reported a net loss of $7.0 million.
That compared with a net loss of $7.3 million in the prior-year quarter.
Basic and diluted net loss per share was $0.07, compared with a loss of $0.08 per share in the second quarter of 2025.
Revenue was approximately $2.6 million, compared with approximately $1.3 million in the prior-year quarter.
The revenue was tied to recognition of portions of upfront and milestone payments from the company’s license agreement with Gilead.
Research and development expenses were $6.3 million.
That compared with $5.6 million in the prior-year quarter.
General and administrative expenses were $2.3 million.
That compared with $2.2 million in the prior-year quarter.
Operating loss was $8.8 million, compared with $8.4 million a year earlier prior-year quarter.
Operating loss was $8.8 million, compared with $8.4 million a year earlier.
Financial and other income helped reduce the net loss.
Compugen ended the quarter with approximately $125.3 million in cash, cash equivalents, short-term bank deposits, and marketable securities.
The company said its cash and cash-related balances are expected to fund operations into 2029.
That estimate does not include any additional cash inflows.
Compugen also said it has no debt.
For a clinical-stage biotech, the cash runway remains one of the most relevant parts of the report because the company is still dependent on clinical progress and partner programs rather than commercial product revenue.
Compugen continued to advance MAIA-ovarian, its randomized, placebo-controlled adaptive platform trial evaluating COM701.
COM701 is a potential first-in-class anti-PVRIG antibody.
The trial is evaluating COM701 as maintenance monotherapy in second- and third-line relapsed platinum-sensitive ovarian cancer.
The company expects median progression-free survival data from the interim analysis by the first quarter of 2027.
Compugen said a clear improvement in progression-free survival versus placebo could help inform a registration path for COM701.
Compugen’s partner AstraZeneca continued advancing rilvegostomig.
Rilvegostomig is a PD-1/TIGIT bispecific antibody, with the TIGIT component derived from Compugen’s COM902 program.
At ASCO 2026, AstraZeneca presented updated data from the GEMINI-Hepatobiliary study in first-line biliary tract cancer.
The study showed median overall survival of 16.8 months.
Compugen said longer follow-up and randomized Phase 3 data will be needed to validate the findings.
AstraZeneca is advancing rilvegostomig across 12 ongoing Phase 3 trials.
GS-0321, formerly known as COM503, continued progressing in a Phase 1 dose-escalation trial.
The program is partnered with Gilead.
GS-0321 is a potential first-in-class anti-IL-18 binding protein antibody designed to harness cytokine biology for cancer treatment.
Compugen said the trial continues to progress as planned.
Compugen’s quarter was mainly a pipeline and cash runway update.
Revenue more than doubled from the prior-year quarter, the net loss narrowed, and the company maintained enough cash to fund operations into 2029. COM701 remained on track for an interim analysis by the first quarter of 2027, while AstraZeneca and Gilead-partnered programs continued progressing.
The key question is whether Compugen’s pipeline can produce clinical data strong enough to support future development, partnerships, or a registration path.
Platforms like LevelFields track layoffs, market catalyst, activist investors, leadership changes, dividend increases, margin expansion, and stock reactions together, helping investors identify when biotech stocks are moving on financial results or pipeline catalysts.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE